title: Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome.
abstract: BACKGROUND
  Polycystic ovary syndrome (PCOS) characterized by chronic anovulation and hyperandrogenism is highly associated with obesity and insulin resistance (IR), two key features of nonalcoholic steatohepatitis (NASH). NASH often leads to cirrhosis, including portal hypertension, liver failure, and hepatocellular carcinoma as long-term complications. The caspase 3-cleaved fragment of cytokeratin 18 (CK18) emerging from ongoing cell death during apoptosis process has been established as a serum marker for NASH. This study was conducted to evaluate the prevalence of NASH in PCOS patients by caspase-cleaved CK18 measurement.
  
  
  METHODS
  In 192 PCOS patients [age, 29.0 +/- 6.7 yr; body mass index (BMI), 31.5 +/- 8.2 kg/m(2)] and 73 age-matched controls (age, 28.6 +/- 8.0 yr; BMI, 24.1 +/- 4.6 kg/m(2)), obesity and IR were determined by BMI and area under the curve of insulin response (AUCI), respectively. Apoptotic cell death was measured by M30 ELISA detecting caspase-cleaved CK18 only.
  
  
  RESULTS
  M30 levels were significantly elevated in PCOS patients after correction for BMI (304.7 +/- 223.1 vs. 86.3 +/- 165.6 U/liter; P < 0.001). M30 correlated significantly with BMI, AUCI, glucose secretion, low-density lipoprotein, low high-density lipoprotein, and free androgen index. AUCI turned out to be the only independent M30-determining factor in the multiple regression analysis with an effect size of 7.9%. Fifty-one of 186 (27.4%) PCOS patients showed M30 levels of at least 395 U/liter, indicating NASH.
  
  
  CONCLUSIONS
  These data demonstrate elevation of apoptotic cell death, its correlation with IR, and a high prevalence of NASH in PCOS patients. Given this high prevalence, PCOS may be a risk factor for progressive hepatic sequelae. Incidence data are of strong interest.
authors.affiliation: Department of Endocrinology and Division of Laboratory Research, University of Duisburg-Essen, 45122 Essen, Germany.
authors.forename: Susanne
authors.initials: S
authors.lastname: Tan
authors.forename: Lars P
authors.initials: LP
authors.lastname: Bechmann
authors.forename: Sven
authors.initials: S
authors.lastname: Benson
authors.forename: Tiina
authors.initials: T
authors.lastname: Dietz
authors.forename: Stefanie
authors.initials: S
authors.lastname: Eichner
authors.forename: Susanne
authors.initials: S
authors.lastname: Hahn
authors.forename: Onno E
authors.initials: OE
authors.lastname: Janssen
authors.forename: Harald
authors.initials: H
authors.lastname: Lahner
authors.forename: Guido
authors.initials: G
authors.lastname: Gerken
authors.forename: Klaus
authors.initials: K
authors.lastname: Mann
authors.forename: Ali
authors.initials: A
authors.lastname: Canbay
mesh_terms: D000328:Adult; D017209:Apoptosis / Q000502:physiology; D015415:Biomarkers / Q000097:blood*; D016022:Case-Control Studies; D018450:Disease Progression; D005234:Fatty Liver / Q000097:blood / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology*; D005260:Female; D006801:Humans; D008659:Metabolic Diseases / Q000453:epidemiology / Q000209:etiology; D010641:Phenotype; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications* / Q000453:epidemiology; D015995:Prevalence; D012307:Risk Factors; D055815:Young Adult
chemical_list: D015415:Biomarkers